ADMA Biologics, Inc. (ADMA)
NasdaqGM · USD · Healthcare · Biotechnology
$11.07 (+3.60%) as of
Key statistics
- Market cap
- 2.48B
- P/E (TTM)
- 15.81
- Forward P/E
- 11.73
- EPS (TTM)
- 0.70
- Dividend yield
- 0.00%
- 52-week range
- 7.21 – 20.46
- Beta
- 0.69
- Revenue (TTM)
- 512.28M
- Profit margin
- 32.98%
- Analyst target
- $17.00
- Volume
- 2.03M
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ramsey, NJ, United States
- Employees
- 640
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.